159 related articles for article (PubMed ID: 36250420)
21. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
22. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
[TBL] [Abstract][Full Text] [Related]
23. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
Ben-Arush M; Minard-Colin V; Scarzello G; Fajardo RD; Terwisscha Van Scheltinga S; Bernier V; Jenney M; Gallego S; Zanetti I; Cesen M; Merks JHM; Bisogno G
Eur J Cancer; 2022 Sep; 172():119-129. PubMed ID: 35763871
[TBL] [Abstract][Full Text] [Related]
24. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
25. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS
Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768
[TBL] [Abstract][Full Text] [Related]
26. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
27. 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
Indelicato DJ; Rotondo RL; Mailhot Vega RB; Uezono H; Bradfield S; Agarwal V; Hol ML; Bradley JA
Acta Oncol; 2019 Oct; 58(10):1404-1409. PubMed ID: 31530120
[No Abstract] [Full Text] [Related]
28. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
29. Advanced embryonal rhabdomyosarcoma of the uterine cervix: a case report.
Smrkolj S; Rakar S; Malić S; Sinkovec J; Kobal B
Eur J Gynaecol Oncol; 2011; 32(2):203-5. PubMed ID: 21614916
[TBL] [Abstract][Full Text] [Related]
30. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
Abd El-Aal HH; Habib EE; Mishrif MM
J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
[TBL] [Abstract][Full Text] [Related]
31. Treatment strategies and outcomes for spinal rhabdomyosarcoma: A series of 11 cases in a single center and review of the literature.
Wang T; Gao X; Yang J; Guo W; Wu Z; Tang L; Cao S; Cai X; Liu T; Jia Q; Xiao J
Clin Neurol Neurosurg; 2020 May; 192():105729. PubMed ID: 32058205
[TBL] [Abstract][Full Text] [Related]
32. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?
Blakely ML; Lobe TE; Anderson JR; Donaldson SS; Andrassy RJ; Parham DM; Wharam MD; Qualman SJ; Wiener ES; Grier HE; Crist WM
J Pediatr Surg; 1999 May; 34(5):736-41; discussion 741-2. PubMed ID: 10359174
[TBL] [Abstract][Full Text] [Related]
33. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Sparber-Sauer M; Ferrari A; Kosztyla D; Ladenstein R; Cecchetto G; Kazanowska B; Scarzello G; Ljungman G; Milano GM; Niggli F; Alaggio R; Vokuhl C; Casanova M; Klingebiel T; Zin A; Koscielniak E; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29691. PubMed ID: 35441463
[TBL] [Abstract][Full Text] [Related]
34. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
35. Embryonal rhabdomyosarcoma: adjuvant and ex vivo assay-directed chemotherapy.
Ballard KS; Tedjarati SS; Robinson WR; Homesley HD; Thurston EL
Int J Gynecol Cancer; 2010 May; 20(4):561-3. PubMed ID: 20442589
[TBL] [Abstract][Full Text] [Related]
36. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
[TBL] [Abstract][Full Text] [Related]
37. Radical surgery and IVA-chemotherapeutic regimen to treat embryonal rhabdomyosarcoma of the urachus: case report.
Fernández EM; Siverio NH; Almaraz RL; Viota LM; Luis JR; Flores LD
Pediatr Hematol Oncol; 2007; 24(7):543-50. PubMed ID: 17786791
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma.
Paulino AC; Simon JH; Zhen W; Wen BC
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1489-95. PubMed ID: 11121653
[TBL] [Abstract][Full Text] [Related]
39. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
40. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
